Risk-Benefit Guidance Aims To Improve Pre-Market Review Predictability
This article was originally published in The Gray Sheet
Executive Summary
It takes more than safety and effectiveness data alone for FDA device reviewers to determine how benefits stack up against risks in a pre-market submission, the agency accentuates in new draft guidance.
You may also be interested in...
FDA’s Final Risk-Benefit Guidance Excludes 510(k)s, Adds De Novo Petitions
Device center reviewers will begin applying the guidance to incoming PMA and de novo submissions and to submissions already under review with decisions beginning on May 1.
Obesity Devices: Planned Risk-Tolerance Survey Could Impact CDRH Decision-Making
A planned survey evaluating obese patients’ tolerance for risk fits into a broader initiative by CDRH to reassess, and in some cases rebalance, how it weighs risks and benefits when making regulatory decisions.
A Long, Strange Trip: 510(k) Reform At One Year
A rundown by “The Gray Sheet” of the most significant 510(k) reform actions taken in 2011, what’s on deck for 2012 and what reform will mean to device makers in the near term.